Gregory M Glenn Insider Trading $NVAX NOVAVAX INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Gregory M Glenn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Gregory M Glenn. Gregory M Glenn is President, R&D in NOVAVAX INC ($NVAX) and SVP, Research and Development in NOVAVAX INC ($NVAX) and Chief Scientific Officer in INTERCELL USA, INC. ($IOMI).
Gregory M Glenn in NOVAVAX INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Gregory M Glenn: President, R&D, SVP, Research and Development
Holdings: 3,430 shares
Current Value: $4,493
Latest Transaction: Apr 19 2021
$NVAX Market Capitalization: $355.26M
$NVAX Previous Close: $1.31
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Gregory M Glenn in NOVAVAX INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 51,643 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 65,628 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 15,221 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 51,643 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 5,737 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 65,628 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 1,242 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 15,221 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 224.50 | 494 | 110,905 | 2,811 | 3.3 K to 2.8 K (-14.95 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 5,737 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 221.67 | 356 | 78,915 | 3,305 | 3.7 K to 3.3 K (-9.72 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 1,242 | |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 220.57 | 437 | 96,390 | 3,661 | 4.1 K to 3.7 K (-10.66 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 224.50 | 494 | 110,905 | 2,811 | 3.3 K to 2.8 K (-14.95 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 219.17 | 81 | 17,753 | 4,098 | 4.2 K to 4.1 K (-1.94 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 221.67 | 356 | 78,915 | 3,305 | 3.7 K to 3.3 K (-9.72 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 218.48 | 153 | 33,428 | 4,179 | 4.3 K to 4.2 K (-3.53 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 220.57 | 437 | 96,390 | 3,661 | 4.1 K to 3.7 K (-10.66 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 217.22 | 284 | 61,691 | 4,332 | 4.6 K to 4.3 K (-6.15 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 219.17 | 81 | 17,753 | 4,098 | 4.2 K to 4.1 K (-1.94 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 216.11 | 417 | 90,117 | 4,616 | 5 K to 4.6 K (-8.29 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 218.48 | 153 | 33,428 | 4,179 | 4.3 K to 4.2 K (-3.53 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 215.01 | 134 | 28,812 | 5,033 | 5.2 K to 5 K (-2.59 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 217.22 | 284 | 61,691 | 4,332 | 4.6 K to 4.3 K (-6.15 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 213.79 | 61 | 13,041 | 5,167 | 5.2 K to 5.2 K (-1.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 216.11 | 417 | 90,117 | 4,616 | 5 K to 4.6 K (-8.29 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 202.09 | 2,260 | 456,723 | 5,228 | 7.5 K to 5.2 K (-30.18 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 215.01 | 134 | 28,812 | 5,033 | 5.2 K to 5 K (-2.59 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 202.09 | 142 | 28,697 | 7,488 | 7.6 K to 7.5 K (-1.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 213.79 | 61 | 13,041 | 5,167 | 5.2 K to 5.2 K (-1.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 202.09 | 4,819 | 973,872 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 202.09 | 2,260 | 456,723 | 5,228 | 7.5 K to 5.2 K (-30.18 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 206.82 | 127 | 26,266 | 2,811 | 2.9 K to 2.8 K (-4.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 202.09 | 142 | 28,697 | 7,488 | 7.6 K to 7.5 K (-1.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 205.69 | 83 | 17,073 | 2,938 | 3 K to 2.9 K (-2.75 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 202.09 | 4,819 | 973,872 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.71 | 152 | 31,116 | 3,021 | 3.2 K to 3 K (-4.79 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 206.82 | 127 | 26,266 | 2,811 | 2.9 K to 2.8 K (-4.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.01 | 391 | 79,767 | 3,173 | 3.6 K to 3.2 K (-10.97 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 205.69 | 83 | 17,073 | 2,938 | 3 K to 2.9 K (-2.75 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 202.85 | 412 | 83,574 | 3,564 | 4 K to 3.6 K (-10.36 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.71 | 152 | 31,116 | 3,021 | 3.2 K to 3 K (-4.79 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 201.93 | 833 | 168,208 | 3,976 | 4.8 K to 4 K (-17.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 204.01 | 391 | 79,767 | 3,173 | 3.6 K to 3.2 K (-10.97 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 200.77 | 605 | 121,464 | 4,809 | 5.4 K to 4.8 K (-11.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 202.85 | 412 | 83,574 | 3,564 | 4 K to 3.6 K (-10.36 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 199.86 | 959 | 191,670 | 5,414 | 6.4 K to 5.4 K (-15.05 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 201.93 | 833 | 168,208 | 3,976 | 4.8 K to 4 K (-17.32 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 198.70 | 717 | 142,465 | 6,373 | 7.1 K to 6.4 K (-10.11 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 200.77 | 605 | 121,464 | 4,809 | 5.4 K to 4.8 K (-11.17 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 197.70 | 873 | 172,594 | 7,090 | 8 K to 7.1 K (-10.96 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 199.86 | 959 | 191,670 | 5,414 | 6.4 K to 5.4 K (-15.05 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 196.77 | 560 | 110,190 | 7,963 | 8.5 K to 8 K (-6.57 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 198.70 | 717 | 142,465 | 6,373 | 7.1 K to 6.4 K (-10.11 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 197.70 | 873 | 172,594 | 7,090 | 8 K to 7.1 K (-10.96 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 196.77 | 560 | 110,190 | 7,963 | 8.5 K to 8 K (-6.57 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Apr 19 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 56,462 | |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 68,752 | |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 16,322 | |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 6,605 | |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 1,861 | |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 225.89 | 129 | 29,140 | 2,811 | 2.9 K to 2.8 K (-4.39 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 224.78 | 375 | 84,292 | 2,940 | 3.3 K to 2.9 K (-11.31 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 223.86 | 164 | 36,713 | 3,315 | 3.5 K to 3.3 K (-4.71 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 221.91 | 60 | 13,315 | 3,479 | 3.5 K to 3.5 K (-1.70 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 219.84 | 180 | 39,572 | 3,539 | 3.7 K to 3.5 K (-4.84 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 218.53 | 114 | 24,912 | 3,719 | 3.8 K to 3.7 K (-2.97 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 217.31 | 402 | 87,357 | 3,833 | 4.2 K to 3.8 K (-9.49 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 216.05 | 421 | 90,955 | 4,235 | 4.7 K to 4.2 K (-9.04 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 215.19 | 459 | 98,771 | 4,656 | 5.1 K to 4.7 K (-8.97 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 213.01 | 57 | 12,142 | 5,115 | 5.2 K to 5.1 K (-1.10 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 211.96 | 57 | 12,082 | 5,172 | 5.2 K to 5.2 K (-1.09 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 210.85 | 5 | 1,054 | 5,229 | 5.2 K to 5.2 K (-0.10 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 217.46 | 2,264 | 492,329 | 5,234 | 7.5 K to 5.2 K (-30.19 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 217.46 | 132 | 28,705 | 7,498 | 7.6 K to 7.5 K (-1.73 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 217.46 | 4,819 | 1,047,940 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 201.47 | 100 | 20,147 | 2,811 | 2.9 K to 2.8 K (-3.44 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 200.15 | 1,282 | 256,586 | 2,911 | 4.2 K to 2.9 K (-30.57 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 199.07 | 1,490 | 296,616 | 4,193 | 5.7 K to 4.2 K (-26.22 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 197.87 | 1,939 | 383,662 | 5,683 | 7.6 K to 5.7 K (-25.44 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 196.88 | 901 | 177,389 | 7,622 | 8.5 K to 7.6 K (-10.57 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Mar 17 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 279.20 | 73 | 20,382 | 2,811 | 2.9 K to 2.8 K (-2.53 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 278.27 | 65 | 18,088 | 2,884 | 2.9 K to 2.9 K (-2.20 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 276.23 | 32 | 8,839 | 2,949 | 3 K to 2.9 K (-1.07 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 274.63 | 48 | 13,182 | 2,981 | 3 K to 3 K (-1.58 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 273.61 | 67 | 18,332 | 3,029 | 3.1 K to 3 K (-2.16 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 272.43 | 205 | 55,848 | 3,096 | 3.3 K to 3.1 K (-6.21 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 271.16 | 110 | 29,827 | 3,301 | 3.4 K to 3.3 K (-3.22 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 269.94 | 319 | 86,109 | 3,411 | 3.7 K to 3.4 K (-8.55 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 269.23 | 678 | 182,536 | 3,730 | 4.4 K to 3.7 K (-15.38 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 268.19 | 268 | 71,875 | 4,408 | 4.7 K to 4.4 K (-5.73 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 266.68 | 128 | 34,135 | 4,676 | 4.8 K to 4.7 K (-2.66 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 265.53 | 361 | 95,854 | 4,804 | 5.2 K to 4.8 K (-6.99 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 264.09 | 80 | 21,127 | 5,165 | 5.2 K to 5.2 K (-1.53 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 4,819 | 28,673 | 61,281 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 3,124 | 18,588 | 71,876 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 46.00 | 1,101 | 50,646 | 17,423 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.60 | 868 | 23,957 | 7,473 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 27.00 | 619 | 16,713 | 2,480 | |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 262.70 | 2,275 | 597,643 | 5,245 | 7.5 K to 5.2 K (-30.25 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | D | 262.70 | 110 | 28,897 | 7,520 | 7.6 K to 7.5 K (-1.44 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 4,819 | 28,673 | 7,630 | 2.8 K to 7.6 K (+171.43 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 296.59 | 66 | 19,575 | 2,811 | 2.9 K to 2.8 K (-2.29 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 294.05 | 13 | 3,823 | 2,877 | 2.9 K to 2.9 K (-0.45 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 291.57 | 413 | 120,419 | 2,890 | 3.3 K to 2.9 K (-12.50 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 289.89 | 125 | 36,236 | 3,303 | 3.4 K to 3.3 K (-3.65 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 288.80 | 9 | 2,599 | 3,428 | 3.4 K to 3.4 K (-0.26 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 287.41 | 147 | 42,249 | 3,437 | 3.6 K to 3.4 K (-4.10 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 286.26 | 148 | 42,367 | 3,584 | 3.7 K to 3.6 K (-3.97 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 285.30 | 59 | 16,833 | 3,732 | 3.8 K to 3.7 K (-1.56 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 284.25 | 1,204 | 342,235 | 3,791 | 5 K to 3.8 K (-24.10 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 283.43 | 955 | 270,678 | 4,995 | 6 K to 5 K (-16.05 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 282.13 | 653 | 184,233 | 5,950 | 6.6 K to 6 K (-9.89 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 281.64 | 522 | 147,015 | 6,603 | 7.1 K to 6.6 K (-7.33 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 280.71 | 156 | 43,790 | 7,125 | 7.3 K to 7.1 K (-2.14 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 278.98 | 236 | 65,840 | 7,281 | 7.5 K to 7.3 K (-3.14 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 277.09 | 377 | 104,461 | 7,517 | 7.9 K to 7.5 K (-4.78 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 275.83 | 129 | 35,582 | 7,894 | 8 K to 7.9 K (-1.61 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 274.80 | 225 | 61,829 | 8,023 | 8.2 K to 8 K (-2.73 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 273.40 | 137 | 37,455 | 8,248 | 8.4 K to 8.2 K (-1.63 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 272.42 | 138 | 37,593 | 8,385 | 8.5 K to 8.4 K (-1.62 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 3,124 | 18,588 | 8,523 | 5.4 K to 8.5 K (+57.86 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 46.00 | 1,101 | 50,646 | 5,399 | 4.3 K to 5.4 K (+25.62 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.60 | 868 | 23,957 | 4,298 | 3.4 K to 4.3 K (+25.31 %) |
| Feb 18 2021 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 27.00 | 619 | 16,713 | 3,430 | 2.8 K to 3.4 K (+22.02 %) |
| Dec 16 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | A | 0.00 | 9,300 | 0 | 9,300 | |
| Dec 16 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | A | 129.70 | 18,700 | 2,425,390 | 18,700 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 25,000 | 148,750 | 75,000 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 109.21 | 1,100 | 120,126 | 1,561 | 2.7 K to 1.6 K (-41.34 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 108.39 | 3,145 | 340,889 | 2,661 | 5.8 K to 2.7 K (-54.17 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 107.30 | 5,789 | 621,140 | 5,806 | 11.6 K to 5.8 K (-49.93 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 106.17 | 9,915 | 1,052,689 | 11,595 | 21.5 K to 11.6 K (-46.09 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 117.07 | 551 | 64,503 | 21,510 | 22.1 K to 21.5 K (-2.50 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 116.08 | 951 | 110,389 | 22,062 | 23 K to 22.1 K (-4.13 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 115.23 | 1,003 | 115,577 | 23,012 | 24 K to 23 K (-4.18 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 113.81 | 401 | 45,639 | 24,015 | 24.4 K to 24 K (-1.64 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 113.02 | 727 | 82,168 | 24,416 | 25.1 K to 24.4 K (-2.89 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 111.92 | 216 | 24,175 | 25,143 | 25.4 K to 25.1 K (-0.85 %) |